Polyphor launches IPO on SIX Swiss Exchange and sets price range Freitag, 27. April 2018 - 07:02

Polyphor, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibiotics and other specialty pharma products for severe or life-threatening diseases, today announces the launch of its initial public offering (“IPO”) and its listing on the SIX Swiss Exchange. The price range for the offered shares has been set at CHF 30 to CHF 40 per share and the Company is targeting gross proceeds of approximately CHF 100 million to CHF 150 million.

For further information, please refer to the attached press release.

Today’s Media Conference at 08:30 CET

Polyphor will hold a media conference today, 27 April 2018 at 08:30 CET. The event will take place at Au Premier Restaurant (Zurich main station), Zurich. Giacomi Di Nepi, CEO, Debra Barker, CMO, and Kalina Scott, CFO, will inform about the planned IPO and provide further insight into Polyphor‘s business and prospects. Registration is not required.

Kind regards,

Polyphor AG